Sionna Therapeutics, Inc. Fair Value Disclosure
| December 31, 2025 | |||||||||||||||||||||||
| Total | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets | |||||||||||||||||||||||
| Cash equivalents: | |||||||||||||||||||||||
| Money market funds | $ | 51,962 | $ | 51,962 | $ | — | $ | — | |||||||||||||||
| Commercial paper | 5,988 | — | 5,988 | — | |||||||||||||||||||
| Marketable securities: | |||||||||||||||||||||||
U.S. Treasury securities | 192,065 | 192,065 | — | — | |||||||||||||||||||
| Commercial paper | 24,396 | — | 24,396 | — | |||||||||||||||||||
| Government agency securities | 23,575 | — | 23,575 | — | |||||||||||||||||||
| Corporate debt | 11,815 | — | 11,815 | — | |||||||||||||||||||
| Total financial assets | $ | 309,801 | $ | 244,027 | $ | 65,774 | $ | — | |||||||||||||||
| December 31, 2024 | |||||||||||||||||||||||
Total | Level 1 | Level 2 | Level 3 | ||||||||||||||||||||
| Assets | |||||||||||||||||||||||
| Cash equivalents: | |||||||||||||||||||||||
| Money market funds | $ | 37,288 | $ | 37,288 | $ | — | $ | — | |||||||||||||||
Marketable securities: | |||||||||||||||||||||||
U.S. Treasury securities | 70,679 | 70,679 | — | — | |||||||||||||||||||
| Government agency securities | 36,415 | — | 36,415 | — | |||||||||||||||||||
| Corporate debt | 17,227 | — | 17,227 | — | |||||||||||||||||||
| Commercial paper | 5,934 | — | 5,934 | — | |||||||||||||||||||
Total financial assets | $ | 167,543 | $ | 107,967 | $ | 59,576 | $ | — | |||||||||||||||
Want the next Sionna Therapeutics, Inc. fair value disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Sionna Therapeutics, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
About Fair Value Disclosures
Fair value disclosures classify all assets and liabilities measured at fair value into a three-level hierarchy: Level 1 (quoted market prices), Level 2 (observable inputs like yield curves), and Level 3 (unobservable inputs requiring management estimates). The proportion of Level 3 assets directly reflects how much of the balance sheet depends on internal models rather than market evidence.
Key signals: a growing Level 3 balance relative to total fair-value assets increases valuation uncertainty and earnings volatility risk. Watch for transfers between levels — assets moving from Level 2 to Level 3 often signal deteriorating market liquidity. Unrealized gains and losses on Level 3 positions flow through earnings or other comprehensive income, so large swings deserve scrutiny. For financial institutions, examine the sensitivity disclosures that show how Level 3 valuations change under alternative assumptions. Compare the fair value of debt against its carrying amount to gauge hidden leverage.